Fragile X Syndrome (FXS) Market Companies, Diagnosis, Treatment and Market Report Scope

Fragile X Syndrome (FXS) Market Companies, Diagnosis, Treatment and Market Report Scope

The Fragile X Syndrome Market report on gives adjusted data which has the mix of the past, current and future information that assists with understanding the Global Fragile X Syndrome Market better. As such, it is a thorough rundown of the multitude of significant variables that are identified with expanding request development with regards to the market across the world. The report likewise gives subtleties of future prospects which have the most recent patterns that are to be found in the coming a long time in this focused on Fragile X Syndrome Market


Download free sample copy here-  


About Fragile X Syndrome Disease

Non‐cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production, and recurrent pulmonary infections. Non‐cystic fibrosis bronchiectasis often coexists with other respiratory conditions, such as chronic obstructive pulmonary disease.


Fragile X Syndrome Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Fragile X Syndrome Companies

  • Zynerba Pharmaceuticals
  • Confluence Pharmaceuticals
  • Tetra Therapeutics
  • Ovid Therapeutics
  • Neuren Pharmaceuticals


Fragile X Syndrome Diagnosis

Initially, the diagnosis of FXS was made through karyotype, which allowed the observation of the distal narrowing of the long arm of the X chromosome in the band 27.3 (Xq27.3-23.8) using the light microscope. The findings of distal constrictions can be done in different chromosomes, and are known as fragile sites, from where FXS is named. Nowadays, there are several molecular tests available for the diagnosis of FXS, which are far more sensitive and specific than the karyotype. Besides allowing the diagnosis of patients with the FM and FXS, these tests allow the identification of carriers of the PM, which are individuals typically with a normal IQ. Still, the female carriers have a high risk of having children with FXS. There are molecular tests that allow the quantification of messenger RNA (mRNA) and FMRP protein, allowing a better understanding of the physiopathology of the disease by correlating the results to the phenotype of the FM and PM patients.

 Polymerase chain reaction (PCR) and Southern blot are the routine tests for the DNA diagnosis of FXS, which allow determining the number of CGG repeats and the methylation status of the FMR1 gene. The PCR through the use of specific primers for the FMR1 gene allows the amplification of the region that contains the CGG repeat and, can identify patients with an expanded FMR1 allele particularly in the premutation but also in the full mutation range.


Fragile X Syndrome Market Report

Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3. It leads to a hyper methylated region in the gene promoter, therefore, silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation. Also, FXS is considered the most common inherited cause of intellectual disability and the second most prevalent cause after Down syndrome.


Fragile X Syndrome Treatment Market

There is no single treatment for FXS, but some treatments help minimize the symptoms of the condition. The treatment regimen of FXS include the use of stimulants, selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics and alpha agonists. The market is expected to grow by the factors like expected entry of emerging therapies with novel targets and pricing. Furthermore, the impending products such as Zygel, Acamprosate, BPN14770, OV101, and Trofinetide are anticipated to expand the market with more penetration in the 7MM markets.


Fragile X Syndrome Market Outlook

FXS is the known leading cause of inherited intellectual disability and an autism spectrum disorder. Currently, there is no approved treatment for FXS. The treatment relies on the associated symptoms of the disease which are typically managed using pharmacologic interventions, such as stimulants for attention deficit and hyperactivity, selective serotonin reuptake inhibitors (SSRIs) for anxiety, antipsychotic drugs for aggression and mood instability, and melatonin for sleep. In boys with FXS, the most frequently used medications are stimulants. These medications are targeted toward the symptoms of hyperactivity, impulsivity, and distractibility and can be quite helpful in these areas. Despite being the most common medication in FXS, the efficacy of these drugs and their side effects vary for each individual. Stimulants may induce irritability and other behavioral problems in children


Fragile X Syndrome Market: Report Scope

  • The report covers the descriptive overview of Fragile X Syndrome (FXS), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the fragile X Syndrome (FXS) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Fragile X Syndrome (FXS) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Fragile X Syndrome (FXS) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MMFragile X Syndrome (FXS) market


Download free sample copy here- 


Following is the table of content of Fragile X Syndrome market report

1 Key Insights

2 Fragile X Syndrome (FXS): Patient Overview at a Glance

3 Executive Summary

4 SWOT Analysis

5 Disease Background and Overview: Fragile X Syndrome (FXS)

6 Recognized Establishments

7 Epidemiology and Patient Population: Fragile X Syndrome

8 Current Treatment

9 Unmet Need

10 Emerging Drugs

11 Other Products

12 Market Size: Fragile X Syndrome

13 Attribute Analysis

14 Conjoint Analysis

15 7MM Market Outlook

16 Market Access and Reimbursement

17 Case Reports

18 Market Drivers

19 Market Barriers

20 KOL Views

21 Appendix

22 Report Methodology

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight


Fragile X Syndrome Market: Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Fragile X Syndrome (FXS).
  • To understand the future market competition in the Fragile X Syndrome (FXS) market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Fragile X Syndrome (FXS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Fragile X Syndrome (FXS) market.
  • To understand the future market competition in the Fragile X Syndrome (FXS) market.


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States